Zika virus (ZIKV) is a flavivirus that is primarily transmitted by Aedes aegypti, the mosquito vector also important in transmission of the flaviviruses responsible for dengue fever, yellow fever, and chikungunya. Because of occurrence in the same geographic regions, serologic cross-reactivity, and similar but often less severe clinical manifestations, such as dengue and chikungunya infections, ZIKV infection likely has gone undetected, misdiagnosed, or both for many years. ZIKV is somewhat unique among flaviviruses in its ability to also be transmitted through sexual contact, nonsexual body fluids, and perinatally. The relatively recent detection of the link between ZIKV infection and Guillain-Barr e syndrome and fetal neurological defects, including microcephaly, has prompted intense efforts aimed at the development of new and specific diagnostic tests. Infection with ZIKV has been postulated to lead to a more severe clinical course from other structurally related viruses, especially dengue, and vice versa because of a phenomenon termed antibody-dependent enhancement. Inactivated whole virus, DNA, RNA, and vectored vaccine approaches to prevent ZIKV infection are in development, as are treatments for active disease that are safe in pregnant women. Here we summarize the important epidemiologic and clinical features of ZIKV infection, as well as the progress and challenges in developing rapid point-ofcare diagnostic tests and vaccines to prevent disease. We used electronic databases to identify relevant published data regarding ZIKV MeSH searches. (J Allergy Clin Immunol 2018;141:482-90.) 
Zika virus (ZIKV), a member of the flavivirus family, is a mosquito-borne arbovirus first identified in a rhesus monkey in the Zika forest in Uganda, East Africa, in 1947. 1 Although the first human infection was reported more than 50 years ago, there were relatively few human infections documented in the literature, and these occurred in tropical Africa and Asia. 2 Human infection was thought to be rare and not clinically important because the reported cases were of mild febrile illnesses that did not result in major sequelae. Because of serologic cross-reactivity and similar clinical manifestations with closely related viruses, such as dengue, ZIKV infection was likely undetected, misdiagnosed, or both as it spread throughout Africa and Asia. Over the last decade, ZIKV has emerged as an important pathogen linked to Guillain-Barr e syndrome and microcephaly in congenitally infected infants. In this review we summarize the epidemiology, structure, transmission, clinical manifestations, diagnosis, immunology, and preventative and active treatment measures for ZIKV.
EPIDEMIOLOGY
ZIKV, like many other flaviviruses, is primarily a vector-borne infection, with its primary vector being Aedes aegypti, the yellow fever mosquito. The biology of A aegypti makes it a particularly efficient vector for infecting human subjects with arboviruses. A aegypti is highly anthrophilic, feeding primarily on human subjects. 3 It prefers to associate closely with human subjects, breeding in small-to medium-sized containers or plants with stagnant water (eg, flower pots, coffee cups, bromeliads, buckets, and discarded tires) and often resting indoors after taking a blood meal. Thus it is commonly found at high densities in impoverished urban environments and can be quite difficult to control by using conventional aerial or ground-based insecticide application procedures.
These characteristics contributed to the explosive spread of ZIKV seen in French Polynesia, Brazil, and the Caribbean islands during the 2015-2016 transmission seasons. For example, the first large outbreak of ZIKV, heralding the current pandemic, occurred in 2007 on Yap Island in Micronesia. 4 A postoutbreak seroprevalence survey suggested that roughly 75% of residents aged 3 years and older had been infected with the virus. 4 Similarly, the first reports of ZIKV transmission in Brazil appeared in early 2015 in the northeastern part of the country. By the end of 2015, between 400,000 and 1.3 million cases were recorded in 14 of Brazil's 26 states. 5 Local transmission of ZIKV was first reported in the United States in Miami Beach, Florida, in August 2016. 6 A total of 218 locally transmitted cases of ZIKV were reported in Florida in 6 with all but one of these occurring in southern Florida, primarily in the Miami Beach area. 4 Local transmission was also reported in Texas, with 6 cases in 2016. A total of 48 cases locally acquired by other means were also reported in 2016 (46 sexual transmissions, 1 laboratory-acquired transmission, and 1 unknown transmission). 6 One case of local transmission was reported in the United States in 2017, as of October 18, 2017, and 3 cases of sexual transmission have been found. 7 Although transmission of ZIKV can be explosive under certain conditions, infecting a large proportion of the population (Fig 1) , most of the resulting infections result in either no or quite mild symptoms. A recent study comparing seroprevalence rates to reported symptomatic infections in French Polynesia after the 2013 outbreak reported an asymptomatic/symptomatic ratio of 1:1 in the general population and a significantly higher asymptomatic/symptomatic ratio of 2:1 among school children. 8 
ZIKV DESCRIPTION
As noted, ZIKV is a member of the Flaviviridae, a family of viruses that includes such human mosquito-borne pathogens as dengue, yellow fever, chikungunya, and West Nile viruses. Flaviviruses have a positive sense RNA genome of approximately 11,000 nucleotides, which encodes a single polyprotein that is posttranslationally cleaved into structural and nonstructural components, each of which encodes distinct functions in the viral lifecycle. 9 The structural proteins are located at the N-terminus of the polyprotein and consist of the premembrane, membrane, envelope, and capsid proteins (Fig 2) . The premembrane and envelope proteins are transmembrane proteins that form the heterodimeric surface lattice of the enveloped flavivirus virion. Processing of premembrane and envelope proteins requires the cellular signalase, whereas maturation of the premembrane to membrane protein requires furin. The envelope protein is responsible for viral attachment and fusion to the host cell. Premembrane-envelope proteins have contacts with the capsid protein to produce the mature enveloped virion.
The C-terminal portion of the polyprotein contains the 8 nonstructural proteins (NSs), which are released by means of cleavage by the viral protease. NS1 is involved in innate immune evasion and associates with replication complexes. NS2B/NS3 encodes the protease responsible for processing the nonstructural portion of the flavivirus polyprotein. NS3 encodes an RNA helicase and is a necessary cofactor for the viral polymerase. NS4B has immune evasion functions. NS5 encodes the viral RNA-dependent RNA polymerase, as well as a methyltransferase activity for capping the viral genome. In addition, NS5 antagonizes the type I interferon response by targeting the signaling molecule signal transducer and activator of transcription 2 for proteasomal degradation. 10 Phylogenetically, ZIKV segregates into 2 distinct clades: African and Asian/American.
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A hallmark of the American lineage is rapid evolution and diversification as ZIKV spreads.
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VECTOR-BORNE TRANSMISSION
Although mosquito-borne flaviviruses are mainly transmitted by A aegypti, Aedes albopictus and a variety of other Aedes species mosquitoes can also transmit these pathogenic viruses, including ZIKV.
14 There are conflicting data suggesting that other mosquitoes, principally Culex species, which transmit Japanese encephalitis and West Nile viruses, might also be involved in ZIKV transmission. 15, 16 
SEXUAL AND BODILY FLUID TRANSMISSION OF ZIKV
Increasing incidences of bidirectional, asymptomatic, and symptomatic sexual transmission of ZIKV have been documented, a feature unique among arboviruses. [17] [18] [19] It is likely that sexual transmission had been occurring previously in endemic regions globally before several recent reports, [19] [20] [21] [22] but this was difficult to confirm because of confounding factors of prior flavivirus infection or logistical laboratory constraints.
Forty-six confirmed sexually transmitted ZIKV cases occurred in the United States contemporaneously to the 2015-2016 ZIKV epidemic in South and Central America from men to women, women to men, and men to men, 23 encompassing routes of vaginal, oral, and anal insertive sexual intercourse, with both asymptomatic and symptomatic disease. 24, 25 Thus, for locally acquired ZIKV in the United States in 2016, sexual transmission accounted for 17% (46/272) of autochthonous cases: of the total 5102 cases reported, 4830 were imported, 224 through a local mosquito vector, and 46 were sexually transmitted (2 through other routes). 26 Sexual transmission of ZIKV appears to be a particularly efficient and direct route for inoculating the unborn, 27 arguably with a potentially higher viral inoculum than through 1 mosquito bite alone. 28 A model of ZIKV vaginal inoculation in immunodeficient mice led to disseminated ZIKV in the entire reproductive tract, including the ovaries and uterus, with spread to the central nervous system and lymphatic systems. 27 Furthermore, male mice demonstrate testicular atrophy caused by ZIKV and might indicate long-term infertility caused by testicular scarring, although data in human subjects are not yet confirmatory. 29 It appears that early ZIKV replication in the vagina is not controlled by traditional humoral T-and B-cell immunity but that type I interferon responses are required to prevent viral spread. 27 Nonsexual body fluid transmission has also been demonstrated from a symptomatic host to a family member with an extremely high viremic load, presumably from exposure to ZIKV present in sweat, saliva, or tears.
PERINATAL TRANSMISSION
Transplacental transmission as a result of initial mosquito or sexual contact continues to be the most concerning outcome of ZIKV propagation, with a spectrum from subclinical to devastating neurological fetal and perinatal sequelae, especially serious fetal neurological problems. 30 The latter include various brain abnormalities with or without microcephaly, as well as eye abnormalities (Fig 3) . This phenomenon reflects susceptibility of human embryonic cortical neural progenitor cells to ZIKV with the subsequent induction of apoptosis. Honein et al 31 estimated the prevalence of birth defects after maternal ZIKV infection by interrogating the US ZIKV Pregnancy Registry from January to September 2016. They noted that among 442 completed pregnancies with laboratory evidence of a recent infection, ZIKV-associated birth defects were present in 6% (95% CI, 4% to 8%) of fetuses or infants. The prevalence of birth defects was similar irrespective of whether maternal infection was symptomatic or asymptomatic (6% each). They noted a 2-fold increase in anomalies after fetal loss (10.6%) compared with livebirths (5.3%). Of affected fetuses and infants, 69.2% had microcephaly. Other reported brain abnormalities included intracranial calcifications, corpus callosum abnormalities, abnormal cortical formation, cerebral atrophy, ventriculomegaly, hydrocephaly, and cerebellar abnormalities. Birth defects were more common among pregnancies in which symptoms appeared in the first trimester (11%; 95% CI, 6% to 19%) compared with the second (0%; 95% CI, 0% to 5%) or third (0%; 95% CI, 0% to 11%) trimesters. As noted above, a second major public health challenge posed by ZIKV is sexual transmission, a feature unique among arboviruses. 32 A third and related challenge is the prolonged persistence of ZIKV in semen (6 months) and maternal plasma (up to 10 weeks), although the precise duration of potential infectivity is unknown.
Other challenges posed by ZIKV to obstetric care providers include (1) uncertainty as to the timing of infection for women living in or traveling through endemic areas or whose partner was so exposed, given that up to 80% of infections are asymptomatic; (2) persistent viremia, viruria, and IgM positivity in pregnancy for weeks to months after exposure; and (3) uncertainty as to the most effective surveillance strategy to detect fetal anomalies. Diagnostic and surveillance strategies are updated regularly by the US Centers for Disease Control and Prevention. 33 
ZIKV-INDUCED CLINICAL MANIFESTATIONS
The typical clinical features of ZIKV infection are relatively nonspecific, and only 20% to 25% of subjects infected with ZIKV have symptoms, making it difficult to detect or diagnose infection. 2, 14, [34] [35] [36] [37] [38] Furthermore, ZIKV infection can occur concomitantly with other infections, making it more difficult to identify. The incubation period of ZIKV is 3 to 12 days, and the disease is often mild and self-limited, with symptoms usually resolving within 7 days. Determining symptom onset is often difficult because unlike dengue and chikungunya virus infections, there is typically no abrupt clinical onset. Furthermore, in some cases the evolution of the disease can be biphasic. Usual clinical manifestations of ZIKV disease include a low-grade fever; maculopapular rash, which can be pruritic; arthralgias (particularly in the smaller joints of the hands and feet); nonpurulent conjunctivitis; myalgias; and headaches (Fig 4) . Asthenia, transient hearing loss, hematospermia, and, less frequently, abdominal pain, nausea, and diarrhea can occur with ZIKV disease. Acute-onset, self-resolving, placoid, or multifocal nonnecrotizing chorioretinal lesions as a feature of active ZIKV chorioretinitis, as reported in other flavivirus infections in adults, have also been reported.
The surge in ZIKV disease has been accompanied by an increase in the number of reported cases of Guillain-Barr e syndrome after ZIKV infection. Guillain-Barr e syndrome is an autoimmune disease leading to destruction of the myelin sheath that surrounds the axons of peripheral nerves or the axons themselves. Overlap between the ZIKV polyprotein and human proteins related to myelin, demyelination, and axonal neuropathy has been described recently, 39 and this finding supports crossreactivity as a potential pathogenic mechanism associating ZIKV infection with Guillain-Barr e syndrome. In patients with ZIKV disease, bilateral facial palsy occurs frequently. Most patients present with tingling sensations in the legs and varying degrees of weakness. The weakness tends to be symmetric in nature and can spread until severe in nature, causing almost total paralysis and requiring mechanical ventilation and intensive care. The majority of patients have complete recovery. Acute treatment typically involves use of intravenous immunoglobulin. Other neurological complications after ZIKV disease include meningoencephalitis and transverse myelitis. 39 Most patients with ZIKV disease have normal hematologic and biochemical laboratory parameters. During the acute phase of J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 illness, increased erythrocyte sedimentation rate and C-reactive protein levels have been reported. Dengue and chikungunya virus infections often occur in the same geographic regions and are transmitted through the same Aedes species mosquito vectors. All 3 viral diseases share overlapping clinical and laboratory characteristics, thereby posing a challenge to distinguish them and prompting the need for definitive diagnostic tests (Table I) . 38 Differentiating clinical features of ZIKV disease from dengue fever and chikungunya fever include a lack of hemorrhagic complications (often present in dengue fever), less severe headache fever and malaise, more prominent extremity edema, and retro-orbital pain. In addition, rash is a more common finding in patients with ZIKV disease and typically starts in the face and spreads downward compared with the rash caused by dengue virus, which is often described as a generalized confluent rash with areas of sparing. The rash in patients with ZIKV disease is more often pruritic. Unlike dengue virus infection, severe illness requiring hospitalization and death are rare complications of ZIKV disease. Transient increases in serum transaminase levels, numbers of activated lymphocytes, and thrombocytopenia have been described with ZIKV infection but cannot be used to differentiate between ZIKV and dengue or chikungunya virus infections. ZIKV infection-associated birth defects, especially the neurologic complications of neonates, are the most significant consequences of ZIKV infection, as discussed above.
DIAGNOSTIC TESTS FOR ZIKV INFECTION
The development of diagnostic tests for ZIKV infection has been an area of intensive research since the beginning of the recent pandemic in 2015. The approaches taken have tended to recapitulate the proved methodologies used to diagnose other flavivirus infections and fall into 2 broad categories: (1) detection of viral genomic sequences and (2) detection of antibodies developed by patients in response to exposure to ZIKV.
Detection of viral genomic sequences using nucleic acid amplification tests (NAATs) remains the gold standard for diagnosing ZIKV infections. The US Centers for Disease Control and Prevention (CDC) recommends using ZIKV-specific NAATs for this purpose. 40 The US Food and Drug Administration has approved several such tests, 41 most of which are based on the RT-PCR format. Multiplex RT-PCR and isothermal amplification tests have also been developed, which are capable of detecting arboviruses that are coendemic with ZIKV, including dengue and chikungunya viruses. 42, 43 However, these tests have not yet received full US Food and Drug Administration approval, and their clinical utility has not been evaluated fully. Several other NAATs have been developed that offer advantages over the 44, 45 Initially, the CDC recommended that NAATs be applied to serum samples. Because viral RNA can be detected in urine for at least as long as in serum, 46 urine is now the specimen of choice for ZIKV NAATs. However, recent studies have suggested that viral RNA sequences are not particularly stable in unprocessed urine samples and that the addition of nucleic acid preservation agents might be necessary to preserve viral RNA in samples not processed immediately. 47 Although NAATs offer a high degree of sensitivity and specificity for ZIKV detection, they are only useful when the virus is circulating, generally less than 14 days after infection. When it is necessary to determine whether a subject was exposed to ZIKV outside of this window, the CDC recommends serologic tests for antibodies to the virus. 40 These assays detect IgM antibodies that generally appear shortly after an acute infection and then decrease relatively rapidly. These IgM-based ELISAs are thus of use in detecting recent ZIKV infections. However, studies have shown a significant amount of cross-reactivity in the ZIKV IgM-based ELISAs in subjects infected with dengue virus. Because dengue virus is by far the most common arboviral infection in the world and typically occurs in areas where ZIKV is endemic, this represents an important limitation of this assay. IgG responses to flaviviruses are often cross-reactive and are thus not necessarily determinative of a response to a particular virus. Thus the development of serologic assays with improved specificity for ZIKV remains an important research priority.
ZIKV TREATMENT
Although currently in the experimental phase, ZIKV treatments include antivirals, antimetabolites, and immunoglobulins. 48 Antivirals, such as IFN-a and ribavirin, have been proposed, but because of side effects and potential teratogenicity, these have not been widely accepted. Recently, the hepatitis C virus NS5 inhibitor sofosbuvir has been shown to be effective against ZIKV both in cell culture and in mice. 49, 50 Antiparasitic agents, such as suramin, have shown promise, with dose-dependent decreases in intracellular ZIKV RNA levels and a greater than 3 log reduction in infectious progeny titers. 51 Nitazoxanide and its bioactive metabolite, tizoxanide, are shown to have anti-ZIKV potential in vitro. 52 Ongoing work is in process for pre-exposure and postexposure medication trials in hopes of preventing transmission along the malaria model and also eradicating potential ZIKV reservoirs with a postexposure prophylaxis protocol.
ZIKV IMMUNOLOGY
Induction of neutralizing antibodies has been shown to be the hallmark of protection for a variety of viral vaccines. This appears to be similar in the case of ZIKV. In preclinical models passive transfer of neutralizing antibodies has been shown to be protective against ZIKV infection. 53, 54 One complication is that flavivirus infection is known to induce cross-reactive antibodies that recognize more than 1 flavivirus. 55, 56 This can be problematic for vaccine efficacy because ZIKV and dengue virus share a mosquito vector and cocirculate in many regions. 57 An additional complication of flavivirus cross-reactivity is the phenomenon of antibody-dependent enhancement, which was first noted in the context of secondary infection with different dengue virus serotypes. [58] [59] [60] [61] Antibody-dependent enhancement can result from recognition of flaviviruses by nonneutralizing cross-reactive antibodies that then can bind to Fc receptors and facilitate uptake and infection of Fc-bearing cells. This process leads to activation of the infected immune cells and profound cytokine release, with the consequent development of a ''cytokine storm'' that results in a high degree of morbidity and potential lethal consequences.
At present, it is unknown whether subjects with previous dengue virus immunity have a more severe ZIKV infection or have a higher risk of fetal transmission of the virus. It is also not proved whether anti-ZIKV antibodies affect the severity of subsequent dengue virus infection. 60, 61 Nonetheless, experimental evidence in an animal model has shown that passive transfer of serum from dengue virus-or West Nile virus-immune volunteers can enhance ZIKV infection and pathogenesis. 59 On the other hand, anti-flavivirus antibody cross-reactivity can provide an opportunity to develop vaccines that protect against multiple distinct viruses, allowing for more efficient vaccination campaign strategies. Indeed, Barba-Spaeth et al 62 have identified a conserved epitope between dengue virus and ZIKV that is recognized by neutralizing antibodies.
The role of T cells in protection from and pathogenesis of ZIKV infection has not been elucidated definitively. However, data exist to support the importance of CD8
1 T cells for control of ZIKV infection. Activation of CD8
1 T cells after ZIKV infection might be important in clearing ZIKV from the central nervous system, thus preventing or lessening neurological complications. CD4
1 T cells polarized to a T H 1 profile with production of IFN-g, TNF-a, and IL-2 have been detected in human subjects infected with ZIKV. Memory ZIKV-specific CD4 1 T cells have been detected in the CXCR3
1 T H 1 compartment, suggesting effector CD4 1 T-cell responses occur as a result of ZIKV infection. 60, 61 Knowledge gained from studies examining the immunologic consequences of ZIKV infection will be critical to develop specific and rapid diagnostic tests, as well as effective vaccines.
PREVENTION AND VACCINES
Development of ZIKV vaccines has progressed rapidly since identification of the Brazilian outbreak of ZIKV in 2014. There are currently 47 different ZIKV vaccines in preclinical development and 7 ZIKV vaccines in clinical trials. 63 These different vaccines span the range of different vaccine platforms, from standard technologies, such as inactivated vaccines, to novel selfamplifying mRNAs and exosomes. This review will focus on those technologies that are being tested in human subjects (Table II) .
Inactivated virus
Inactivated ZIKV vaccines, either with or without adjuvant, have been developed [60] [61] [62] and shown to be effective against a wide variety of viruses, including flaviviruses, such as Japanese encephalitis and dengue viruses. Preclinical studies showed that purified inactivated virus induced specific neutralizing antibodies and protected animals from subsequent challenge with a wildtype American lineage ZIKV. [64] [65] [66] Purified inactivated virus is J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2
currently being tested in a number of phase 1 clinical trials, both in flavivirus-naive and flavivirus-primed subjects (Table II) .
DNA
Plasmid-based ZIKV vaccines by both the National Institutes of Allergy and Infectious Diseases and Inovio (Plymouth Meeting, Pa; Table II) entailed cloning ZIKV genes into mammalian expression vectors, which can be taken up by dendritic cells after inoculation to express viral proteins. DNA vaccines have the benefits of ease of production in large quantities, stability to adverse storage conditions, and low reactogenicity. 67 The DNA vaccines currently in clinical trials target both the ZIKV premembrane/membrane and envelope proteins. 65, 68 Plasmids are administered either by means of injection or electroporation and direct expression of viral proteins in host cells. Preclinical studies have shown protection in animals against both homologous and heterologous strains of ZIKV.
RNA
Two different technologies for RNA vaccines have been developed in recent years. In self-amplifying RNA vaccines, the gene of interest is inserted into a subgenomic replicon of an RNA virus encoding the viral replication machinery. Replicons have been developed from a range of RNA viruses, including alphaviruses, picornaviruses, and flaviviruses. 69, 70 In mRNA vaccines the antigens of interest are expressed directly from RNA. 69 Both classes of RNA vaccines are introduced with lipid nanoparticles. mRNA vaccines for ZIKV encoding viral surface proteins have been tested successfully in preclinical settings, 71, 72 and a ZIKV mRNA vaccine is currently in phase 1/2 trials (Table II) .
Viral vector
A number of viral vectors expressing ZIKV antigens have been tested in preclinical models with positive results. These vectors include adenoviruses, 73 recombinant vesicular stomatitis virus, 74 and other flaviviruses. 75 The most advanced vectored ZIKV vaccine is a recombinant measles virus expressing the ZIKVenvelope protein developed by the European Vaccine Initiative and Themis Bioscience, which is currently undergoing phase 1 trials (Table II) .
Additional vaccine candidates using these platforms, as well as recombinant subunit, peptide, virus-like particle, and live attenuated vaccines, are currently being tested in preclinical studies. Although it is too early to speculate on which candidates will provide robust immunization without reactogenicity or antibodydependent enhancement of flavivirus disease, the rapid application of current vaccine technologies to ZIKV augurs well for a ZIKV vaccine in the near term and for vaccines for other emerging viruses in the future.
CONCLUSION
Although ZIKV disease is relatively mild, the association of ZIKV disease with the development of Guillain-Barr e syndrome and the potential for perinatal transmission with consequent fetal neurological defects, including microcephaly, makes ZIKV a major public health problem. There is a need to develop rapid and specific tests for ZIKV diagnosis. Furthermore, therapies for active infection, including those safe for pregnant women, need to be developed. Ultimately, disease prevention through vaccination and remediation of Aedes species mosquito reservoirs will be the best strategies for control of ZIKV infection. 
